Amundi Buys 19,010 Shares of Indivior PLC (NASDAQ:INDV)

Amundi lifted its position in Indivior PLC (NASDAQ:INDV) by 12.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 174,434 shares of the company’s stock after purchasing an additional 19,010 shares during the quarter. Amundi owned about 0.13% of Indivior worth $2,109,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Clark Estates Inc. NY grew its holdings in Indivior by 1.3% during the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock valued at $3,199,000 after buying an additional 3,300 shares in the last quarter. VELA Investment Management LLC boosted its position in shares of Indivior by 45.5% during the 4th quarter. VELA Investment Management LLC now owns 179,659 shares of the company’s stock valued at $2,264,000 after acquiring an additional 56,224 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Indivior in the fourth quarter valued at $56,000. China Universal Asset Management Co. Ltd. bought a new stake in Indivior in the fourth quarter worth $359,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in Indivior during the fourth quarter valued at $1,192,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Trading Up 3.2 %

Shares of INDV opened at $9.99 on Tuesday. The company’s fifty day simple moving average is $10.60 and its 200-day simple moving average is $10.47. The company has a market cap of $1.38 billion, a P/E ratio of -28.54 and a beta of 0.82. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $22.53.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million for the quarter, compared to analyst estimates of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. Analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on INDV. Piper Sandler dropped their price objective on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Rodman & Renshaw assumed coverage on Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target for the company. Finally, RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.